Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

lktlabs.com Web:

## **Product Information**

Product ID C211324

CAS No. 1338806-73-7

**Chemical Name** 

Synonym CFI 400945, CFI400945

Formula  $C_{33}H_{34}N_4O_3$ 

Formula Wt. 534.66

**Melting Point** 

Purity ≥98%

Solubility

Store Temp -20°C

Ship Temp Ambient

Description CFI-400945 is an inhibitor of polo-like kinase 4 (PLK4). PLK4 plays an important role in centriole replication, and inhibition of

PLK4 disrupts mitosis. CFI-400945 inhibits tumor growth in models of pancreatic cancer. PLK4 inhibition may be effective against osteosarcoma, where it is theorized that overexpression of PLK4 may be a driving forc ein osteosarcoma development

and preservation. TEST!!!!!!

## **Pricing and Availability**

## Bulk quanitites available upon request

| Size   | List Price            |
|--------|-----------------------|
| 1 mg   | \$75.00               |
| 5 mg   | \$150.00              |
| 25 mg  | \$375.00              |
| 100 mg | \$1075.00             |
|        | 1 mg<br>5 mg<br>25 mg |

References Lohse I., Mason J., et al. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. Oncotarget. 8(2):3064-71 (2017). PMID: 27902970.

> Kelleher F., Kores J., et al. Targeting the centrosome and polo-like kinase 4 in osteosarcoma. Carcinogenesis. 40(4):493-99 (2019). PMID: 30508038.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.